• VE-821 ATR Kinase Inhibitor: Workflows & Troubleshooting Gui

  2026-06-13

  VE-821, a potent ATR kinase inhibitor from APExBIO, empowers precise dissection of DNA damage response and radiosensitization workflows. This guide translates recent research and bench experience into actionable protocols, troubleshooting, and advanced tips for maximizing VE-821 in DNA repair and combination chemotherapy studies.

• MLN8237 (Alisertib): Reliable Aurora A Inhibition for Cancer

  2026-06-12

  This article delivers a scenario-driven, evidence-backed exploration of MLN8237 (Alisertib), SKU A4110, as a selective Aurora A kinase inhibitor for advanced cancer biology workflows. By addressing real-world challenges in cell viability, apoptosis induction, and preclinical assay reproducibility, it guides researchers toward robust, reproducible experimental outcomes with data-driven protocol recommendations.

• Cardiogreen (Indocyanine Green): Enabling Immune-Modulating

  2026-06-12

  Explore how Cardiogreen (Indocyanine green) advances beyond diagnostics to enable immune-modulating phototherapy and ECM remodeling strategies. Uncover unique mechanistic insights and practical assay parameters that distinguish this cornerstone dye in translational research.

• Ceftolozane/Tazobactam: Expanding Options for Resistant Infe

  2026-06-11

  The reference study provides a comprehensive review of ceftolozane/tazobactam, a novel cephalosporin/beta-lactamase inhibitor combination with enhanced efficacy against multidrug-resistant gram-negative pathogens. Its pharmacokinetic profile, mechanism of action, and clinical trial data position it as a significant advancement for treating complicated infections, highlighting the continued need for innovative antibacterial agents.

• Dissecting Aneugenic Mechanisms: Insights from Molecular Tar

  2026-06-11

  The reference study introduces a robust assay framework to mechanistically classify aneugenic chemicals, distinguishing tubulin binders from mitotic kinase inhibitors using flow cytometry and machine learning. These advances provide researchers with scalable tools to elucidate molecular targets underlying chromosome missegregation, informing both toxicology and cancer biology workflows.

• Spirocyclic POM Analogues Targeting MmpL3 in Tuberculosis Re

  2026-06-10

  This study introduces spirocyclic phenyl oxazole methyl (POM) analogues as potent inhibitors of Mycobacterium tuberculosis, with a focus on the MmpL3 transporter—a target without clinically approved drugs. The lead compound demonstrated sub-micromolar activity against clinical isolates, offering hope for new strategies against drug-resistant TB.

• PTT and CD47 Blockade Synergy in OSCC: Mechanisms and Implic

  2026-06-10

  The referenced study demonstrates that combining photothermal therapy (PTT) with CD47 blockade markedly enhances macrophage-mediated clearance of oral squamous cell carcinoma (OSCC). This synergy is driven by PTT-induced calreticulin exposure and extracellular matrix remodeling, offering a dual mechanism to overcome immune evasion and physical barriers in the tumor microenvironment.

• Transmission Dynamics of Carbapenemase Genes in CREC During

  2026-06-09

  This study characterizes the genetic landscape and transferability of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) isolates from eight teaching hospitals in Guangdong, China, collected during the COVID-19 pandemic. The findings reveal high rates of multidrug resistance, predominant plasmid-mediated blaNDM-1 carriage, and efficient horizontal gene transfer, highlighting urgent challenges for infection control and translational antibiotic research.

• Capsazepine Targets MCL1 to Reverse Tamoxifen Resistance in

  2026-06-09

  This study identifies capsazepine as a novel MCL1 inhibitor capable of overcoming tamoxifen resistance in estrogen receptor-positive breast cancer. Through integrated virtual and experimental screening, direct MCL1 binding, and synergy with tamoxifen, capsazepine offers a mechanistically validated strategy to combat endocrine therapy failure.

• MLN8237 (Alisertib): Precision Aurora A Inhibition in Cancer

  2026-06-08

  MLN8237 (Alisertib) offers researchers a highly selective, ATP-competitive Aurora A kinase inhibitor for advanced cancer biology workflows. When optimized, this tool enables robust apoptosis induction and precise dissection of cell cycle and trained immunity mechanisms—empowering translational studies in tumor growth inhibition and immune modulation.

• ampC/ampD Mutations Drive P. aeruginosa Resistance to C/T: P

  2026-06-08

  This study provides a rigorous dissection of ceftolozane-tazobactam resistance in Pseudomonas aeruginosa, linking specific ampC and ampD mutations to quantifiable shifts in drug susceptibility. By applying semi-mechanistic PKPD modeling, the authors differentiate initial and adaptive resistance mechanisms, offering precision insights for antimicrobial research and resistance monitoring.

• Carbapenemase Gene Transmission in CREC: Insights from Guang

  2026-06-07

  This study systematically characterizes the prevalence, genetic diversity, and transmission mechanisms of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong, China. The findings reveal predominant plasmid-mediated blaNDM-1 dissemination, high multidrug resistance, and significant epidemiological trends, offering important context for ongoing antimicrobial resistance research.

• Ceftolozane/Tazobactam and Meropenem: Advances in Gram-Negat

  2026-06-06

  The reference study evaluates ceftolozane/tazobactam, a novel cephalosporin/β-lactamase inhibitor, for complicated Gram-negative infections. Its mechanistic and pharmacodynamic innovations set new benchmarks for treating resistant pathogens, with significant implications for translational infection modeling and comparative research using β-lactam antibiotic carbapenems like Meropenem.

• Oral Faropenem Sodium: AMR Risks and Research Implications

  2026-06-05

  The reference study details how widespread oral faropenem sodium use, particularly in India, is contributing to antimicrobial resistance (AMR) and cross-resistance with vital carbapenems. It underscores the urgent need for rational antibiotic use and highlights gaps in susceptibility testing standards, providing key context for researchers investigating penem antibiotics and AMR mechanisms.

• Ceftazidime in Translational Research: Mechanism and Strateg

  2026-06-05

  Explore how Ceftazidime, a third-generation cephalosporin, empowers translational researchers to confront multidrug-resistant Gram-negative infections—particularly in respiratory models—by integrating mechanistic insights, evidence-based protocol design, and strategic considerations in the era of rapidly evolving resistance.

15239 records 1/1016 page Next 12345 下5页 Last page